Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years old, gender is not limited; 2. Expected survival time ≥3 months; 3. ECOG score 0\~1; 4. Patients who meet the clinical diagnostic criteria and have a clear pathological diagnosis of malignant solid tumors that have failed standard treatment; 5. Tumor tissue samples (specimens within one year are recommended) positive for B7H3 by immunohistochemical (IHC) staining or flow assay; 6. Presence of at least one evaluable lesion according to RECIST V1.1; 7. Tumors limited to peritoneal (metastatic) and ovarian cancer in patients in the laparotomy group; 8. Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before the first treatment with cell injection): Blood: white blood cell count (WBC) ≥3E9/L, lymphocyte count (LY) ≥0.8E9/L, hemoglobin (Hb) ≥80g/L, platelet (PLT) ≥75E9/L; Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; total bilirubin ≤ 3.0 × ULN; Kidney: serum creatinine ≤ 1.5 × upper limit of normal range (ULN); Heart: left ventricular ejection fraction ≥50% on echocardiography; lung: normal oxygen saturation without oxygen. 9. Pregnancy test should be negative for women of childbearing potential and both men and women agree to use effective contraception during treatment and for 1 year thereafter; 10. Be able to understand the requirements and matters of the trial and be willing to participate in the clinical study as required; 11. Sign the trial informed consent form. Exclusion Criteria: 1. Known hypersensitivity, allergy, intolerance, or contraindication to cell infusion or any of the drug components that may be used in the study, including fludarabine and cyclophosphamide; 2. Patients who have been continuously using immunosuppressive drugs within 1 month prior to cell infusion; 3. Cerebrovascular accident or seizure within 6 months prior to signing the informed consent form; 4. Symptomatic brain metastases; 5. a known psychiatric or substance abuse disorder that would interfere with cooperation with the trial requirements; 6. Hepatitis B surface antigen (HBsAg) positivity or hepatitis B core antibody (HBcAb) positivity and a peripheral blood test for hepatitis B virus (HBV) DNA titer that is not within the normal reference range; hepatitis C virus (HCV) antibody positivity and peripheral blood hepatitis C virus (HCV) RNA positivity; human immunodeficiency virus (HIV) antibody positivity; syphilis Positive for syphilis; 7. Serious cardiac disease: including, but not limited to, unstable angina pectoris, myocardial infarction (occurring within 6 months prior to screening), congestive heart failure (NYHA classification ≥ III), and severe arrhythmias; 8. Presence of active or uncontrolled infections requiring systemic therapy (except for mild genitourinary and upper respiratory tract infections); 9. has not recovered from acute toxic effects of prior therapy (prior therapy-induced hematologic or organ toxicity ≥ Grade 2, except for abnormalities related to study disease and medical history); 10. have a confirmed diagnosis of an immunodeficiency 11. suffering from an active infection requiring systemic therapy; 12. a female subject of childbearing potential who plans to become pregnant within 2 years of cell infusion; or a male subject whose partner plans to become pregnant within 2 years of cell infusion; 13. Participation in a clinical study of another innovative drug within 1 month prior to screening;